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Similar expression to FGF (Sef) inhibits fibroblast growth
factor-induced tumourigenic behaviour in prostate cancer
cells and is downregulated in aggressive clinical disease
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BACKGROUND: The fibroblast growth factor (FGF) axis is an important mitogenic stimulus in prostate carcinogenesis. We have
previously reported that transcript level of human similar expression to FGF (hSef), a key regulator of this pathway, is downregulated
in clinical prostate cancer. In this study we further analysed the role of hSef in prostate cancer.
METHODS: hSef function was studied in in vitro and in vivo prostate cancer models using stable over-expression clones. Protein
expression of hSef was studied in a comprehensive tissue microarray.
RESULTS: Stable over-expression of hSef resulted in reduced in vitro cancer cell proliferation, migration and invasive potential. In an
in vivo xenograft model, the expression of hSef significantly retarded prostate tumour growth as compared with empty vector
(P¼ 0.03) and non-transfected (P¼ 0.0001) controls. Histological examination further showed a less invasive tumour phenotype and
reduced numbers of proliferating cells (P¼ 0.0002). In signalling studies, hSef inhibited FGF-induced ERK phosphorylation, migration
to the nucleus and activation of a reporter gene. Constitutively active Ras, however, was able to reverse these effects, suggesting that
hSef exerts an effect either above or at the level of Ras in prostate cancer cells. In a large tissue microarray, we observed a significant
loss of hSef protein in high-grade (Po0.0001) and metastatic (Po0.0001) prostate cancer.
CONCLUSION: Considered together, the role of hSef in attenuating FGF signalling and evidence of downregulation in advanced tumours
argue strongly for a tumour suppressor function in human prostate cancer.
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The fibroblast growth factor (FGF) axis is an important promoter
of tumourigenesis in many malignancies, including prostate cancer
(Grose and Dickson, 2005; Chaffer et al, 2007). Work from our own
group and others have shown significant over-expression of
ligands and receptors in early and late disease (Gnanapragasam
et al, 2003; Kwabi-Addo et al, 2004; Sahadevan et al, 2007).
However, in addition to these components, a separate layer of
endogenous regulators have been shown to significantly modulate
the effect of receptor tyrosine kinase (RTK) signalling. These
molecules include MAP kinase phosphatases, members of the
Sprouty and Spred families and, more recently, similar expression
to FGF (Sef). These act as feedback inhibitory checkpoints at key
steps in the intracellular signalling cascade (Thisse and Thisse,
2005; Mason et al, 2006; Bundschu et al, 2007). The role of these
regulators in malignancies has attracted much attention with
reports of loss of expression in different tumour types (McKie
et al, 2005; Fong et al, 2006; Yoshida et al, 2006; Zisman-Rozen
et al, 2007).
Sef was originally identified by synexpression and association
with the FGF axis in embryogenesis (Furthauer et al, 2002; Tsang
et al, 2002). Sef has since been shown to regulate signalling by
other growth factors (Xiong et al, 2003; Torii et al, 2004). The site
of Sef action remains controversial. In one of the two original
reports in zebrafish, Sef was shown to inhibit ERK activation at the
level of MEK (Furthauer et al, 2002). In the other report, Sef was
shown to immunoprecipitate and colocalise with the FGF receptor
(FGFR) (Tsang et al, 2002). Work with human and mouse Sef has
similarly shown differences with Sef, either acting at the level of
Ras interface or downstream at the level of MEK (Kovalenko et al,
2003; Xiong et al, 2003; Yang et al, 2003; Ren et al, 2006; Ziv et al,
2006). An alternative mechanism has proposed that hSef does not
block ERK phosphorylation but rather affects its substrate
specificity by spatial regulation into the nucleus or cytoplasm
(Torii et al, 2004).
We have previously shown that hSef downregulation enhances
FGF signalling in prostate cancer cells and evidence of loss of
transcript expression in high-grade and metastatic clinical disease
in a pilot cohort of patients (Darby et al, 2006). This finding has
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been corroborated by others who have also shown hSef loss in
breast, ovarian and cervical cancers (Yang et al, 2003; Zisman-
Rozen et al, 2007). These data raise the possibility that loss of hSef
function may be an important common event in the dysregulation
of growth factor signalling in epithelial carcinomas. However, the
controversies on its mechanism of action suggest that its exact
function in a given cell type needs to be carefully characterised. In
this study, our aim was to analyse further the functional effect of
hSef in a cell model of prostate cancer and test the protein expres-
sion pattern of hSef in a large clinical cohort of prostate cancers.
MATERIALS AND METHODS
Constructs and stable cell lines
pCDNA3.1-Sef-Myc, pFA2-ELK-1luc and pFR-Luciferase were gifts
from Professor Z Chang (Tsinghua University, China) and
pHO6T1-H-Ras-HA from Professor J Lunec (Newcastle University,
UK). All plasmids were sequence verified before use. DU145 cells
were seeded into 90mm tissue culture dishes and transfected with
pCDNA3.1-Sef-Myc or empty vector (Superfect, Qiagen, Crawley,
UK) before being placed under G418-sulphate selection for 14–20
days. Individual colonies were removed by trypsinisation and
expanded. Cells were maintained in RPMI 1640 media (Sigma,
Poole, UK) containing 10% foetal calf serum (FCS), termed full
medium (FM). Media lacking FCS was termed basal medium (BM).
Quantitative real-time PCR (QPCR)
Quantitative real-time PCR was performed using a 7900-HT
sequence detection system (Applied Biosystems, Warrington,
UK). Total RNA was extracted using Trizol (Invitrogen, Paisley,
UK) and reverse transcribed (Promega, Southampton, UK)
according to the manufacturer’s instructions. QPCR was per-
formed using SYBR Green mastermix (Invitrogen) and primers
designed using primer express 2.0 (Applied Biosystems) as follows:
hSef forward 50-CAGAACTTCGGCTTCCGTTT-30, hSef reverse
50-CTG CTCACAGGTCTTTCGCTTG-30, GAPDH forward 50-CGA
CCACTTTGTCAAGCTCA-30 and GAPDH reverse 50-GGGTCTTAC
TCCTTGGAGGC-30. Thermocycle conditions for all PCR reactions
were a denaturation stage of 95 1C per 10min, followed by 951C for
15 s and 60 1C for 1min for 40 cycles; a disassociation stage was
performed to ensure single amplicon formation. Levels of
expression were evaluated using the absolute quantification
method normalising against the housekeeping gene GAPDH (ABI
technical bulletin 2, www.appliedbiosystems.com).
Immunofluorescence
Cells were plated at 2000 per well in eight-well BD Falcon slide
chambers (Cowley, Oxford, UK). Cells were starved and treated
with FGF-1 (100 ngml1), FGF-2 (10 ngml1), FGF-8 (100 ngml1)
or FM. Cells were fixed in methanol and primary antibody to
p-ERK (Santa Cruz Biotechnology, Santa Cruz, CA, USA) applied
in a dilution of 1:50 followed by TRITC-conjugated secondary anti-
body (Dako, Ely, UK) (1:200). Slides were mounted using DAPI
containing mountant (Dako) and visualised using a DMR
fluorescent microscope at  400 magnification (Leica Microsys-
tems, Milton Keynes, UK). In Ras studies, 2 mg of pHO6T1-H-Ras
was transfected per well and the above experiments were repeated.
Proliferation assay
Cells were seeded at a density of 3000 per well in 96-well plates.
Cells were starved in BM for 24 h before stimulation with FM and
FGF1, FGF2 or FGF8 (in doses of 0, 1, 10 and 100 ngml1 as
appropriate) for 48 h or at the time intervals indicated. A total of
10% WST-1 reagent (Roche, Lewes, UK) was added to the wells
and colorimetric change was measured at 450 nm on a Specta Max
250 plate reader (Molecular Devices, Crawley, UK). To test the
effects of Ras, 100 ng of pHO6T1-H-Ras were transfected per well
and the above experiments were repeated.
Invasion and scrape assays
A total of 50 000 cells were plated out into BD Falcon migration
chambers in BM. FGF-1, FGF-2, FGF-8 or FM was used in the lower
chamber as the chemo-attractant with an intervening matrigel
layer. Cells were allowed to migrate across a matrigel layer for 16 h
in a humidified tissue culture incubator. Non-migrated cells were
removed from the upper chamber and cells fixed in methanol for
20min at 20 1C and then stained with haematoxylin. Membranes
were removed with a sterile scalpel and mounted on to slides with
DPX and counted using a bright field microscope at  20 mag-
nification. A minimum of four different fields of view were used to
obtain an average count per section. Wound scrape assays were
performed by plated cells at a density of 70 000 cells per well in
six-well plates and left to adhere overnight. A sterile tip was used
to scratch a wound and cells left for 16 h under FM stimulation
before being examined using light microscopy.
Western blotting
Cells were lysed directly using SDS sample buffer containing
10% b- mercaptoethanol. Samples were denatured and separated
using SDS–PAGE, followed by transfer to nitrocellulose mem-
brane. Membranes were blocked with 5% milk in Tris-buffered
saline (TBS; 50mM Tris-HCl (pH 7.5), 150mM NaCl) for 1 h, and
then incubated with primary antibodies (1:500) in diluent (0.1%
milk in TTBS (1% Tween/TBS)) for 1 h at room temperature.
Primary antibody complexes were detected using HRP-conjugated
secondary antibodies and protein bands were visualised using
enhanced chemiluminescence (Amersham, Piscataway, NJ, USA).
Luciferase reporter assays
In luciferase assays, cells were transfected with a total of 150 ng of
DNA per well (24-well plate), comprising 100 ng Elk1-luc or 100 ng
pFR-luciferase, and 50 ng b-galactosidase reporter, starved in
BM for 24 h and then stimulated with FGF1 (0–100 ngml1) FGF2
(0–10ngml1) or FGF8 (0–100 ngml1) (R&D Systems, Abingdon,
UK). Cells were harvested and assayed for luciferase activity
corrected for b-galactosidase activity according to the manufac-
turer’s guidelines (Promega, Southampton, UK).
Prostate xenograft studies
In vivo experiments were reviewed and approved by the
institutional animal welfare committee and performed according
to the UKCCCR guidelines. Male athymic nude mice (CD1 nu nu1,
Charles River, Margate, Kent, UK) were maintained and handled in
isolators under specific pathogen-free conditions. Tumours
(DU145 wild type, DU145-EV and DU145-Sef) were generated by
implantation of 50ml of tumour cell suspension subcutaneously
into one flank of CD-1 nude mice (1  107 cells per animal, n¼ 5
animals in each group for each of the two studies). Two-
dimensional caliper measurements were made and tumour volume
was calculated using the Equation a2 b/2, in which a is the
smallest measurement and b the largest. At the end of study,
tumours were harvested and fixed in formalin before paraffin
embedding. Sample sections were stained with haematoxylin and
eosin or used for immunohistochemistry. Differences in Ki67 stain
between tumours were assessed by calculating the positive nuclei
in four separate fields of view ( 200) to derive a mean value for
each slide. Three slides for each tumour were assessed for an
average score for each tumour.
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Prostate tissue microarray
The tissue microarray used for immunohistochemistry in this
study has been previously developed in our unit and reported
(Sahadevan et al, 2007). Clinical data for the samples included
were collected retrospectively and stored in an anonymous
database. Cases were selected for this array to ensure a good
spread of disease grade, stage and metastatic status. Age-matched
benign tissues from patients with no histological diagnosis of
CaP were also included. Normal tissues, including breast, kidney,
lung and placenta, were included in the microarray. Standard
microtome sectioning method was used to cut 5 mm thickness
sections.
Immunohistochemistry and in situ hybridisation
Antigen retrieval was achieved using 0.01M sodium citrate buffer
(pH 6.0) and microwaving for 2min on full power (1000W) in
a pressure cooker. Anti-hSef (R&D systems) and anti-Ki67
(Santa Cruz) monoclonal antibodies were applied in a dilution of
1:500. The Anti-hSef antibody was raised against recombinant
human Sef (aa 27–299; Acc AAM77571). Analysis of the sequence
confirmed that this antibody would detect the known long and
short isoforms of Sef. To confirm antibody specificity, sections
incubated with the competing Sef antigen (R&D systems) were
used internal negative controls. Secondary labelling was achieved
using biotinylated antibodies (Dako). All sections were counter-
stained with DAB and haematoxylin. Sample sections were viewed
by two independent observers and inter-observer agreement was
obtained regarding a grading system. The level of Sef expression
was assumed to correlate with the strength of the immunoreactivity
signal and scored as either absent or weak (/þ ), moderate
(þ þ ) or strong (þ þ þ ). When two or more signal intensities
were present in one case, the predominant signal was taken as the
score. In in situ hybridisation the cDNA template for the riboprobe
was designed from the unique segment of the long isoform
(AF494208) and incorporated a T7 and T3 promoter (Yorkshire
Biosciences, York, UK). Anti-sense and sense riboprobes were
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Figure 1 Characterisation and in vitro behaviour of hSef expression clones. (A) Expression of hSef in the stable clone was assessed at the transcript level
using QPCR (left panel) and at the protein level using western blot against the Myc tag (right panel). In transcript assay the fold increase in expression is
shown and represents the mean of three studies each performed in triplicate. (B) Proliferation assays using serum-enriched media as a stimulus. In these
studies the mean of three experiments, each repeated in triplicate, is shown and expressed as a fold increase over un-induced cells. (C) In wound scrape
assays the extent of cell migration across a cleared line was compared between DU145-EV and DU145-Sef clones at 16 h. (D) Invasion assays using serum-
enriched media as a stimulus for 16 h. Parallel proliferation experiments were also conducted at 16 h in control DU145 cells to confirm that any change was
not due to an increase in cell numbers (right panel). In wound and invasion studies one representative image of three experiments is shown. In invasion
assays the results are shown as the mean fold change of these in comparison with DU145-EV cells. Proliferation experiments were conducted as described
above (*Po0.005 with error bars representing s.d. from the mean). Abbreviations: BM¼ basal media; FM¼ full media.
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generated after sequence verification. Signals were scored as
described above. Signals were scored as described above. The
technique of in situ hybridisation has been previously described
(Gnanapragasam et al, 2001).
Statistical tests
Statistical analysis for in vitro and in vivo studies was performed
using two-tailed Student’s t-test. Analysis for the clinical data was
further performed by correlating hSef expression with clinical
parameters using the Kruskal–Wallis test. A P-value ofp0.05 was
taken as significant.
RESULTS
hSef inhibits in vitro prostate cancer cell proliferation,
migration and invasion
We have previously shown almost undetectable levels of hSef in the
DU145 prostate cancer cell line, which is also very sensitive to FGF
stimulation (Mehta et al, 2001; Darby et al, 2006). DU145 cells were
stably transfected with empty vector (DU145-EV) or full-length
hSef (DU145-Sef). hSef over-expression was confirmed at the
transcript level using QPCR and at the protein level using western
blot against the Myc tag (Figure 1A). We next analysed the
biological effect of Sef transfection. Stimulation with serum-
enriched media resulted in a significant increase in DU145-EV cell
proliferation (Po0.005; Figure 1B). In contrast, DU145-Sef cells
failed to respond to stimulation. In wound scrape assays, over-
expression of hSef significantly inhibited cell migration across a
cleared line (Figure 1C). In invasion assays we again observed
similar results with hSef significantly reducing cell movement
across a matrigel layer at 16 h (Po0.005; Figure 1D, left and middle
panel). Parallel proliferation experiments confirmed that the four-
fold increase in invasion in control cells was unlikely to be due to
increased cell numbers as there was only a modest change in
proliferation at 16 h (Figure 1D, right panel). These results suggest
that increased hSef expression significantly inhibits prostate
cancer cell behaviour in vitro.
Expression of hSef results in a slow-growing and
less-invasive in vivo tumour phenotype
To analyse the in vivo relevance of hSef expression, parental
DU145, DU145-EV and DU145-Sef cells were implanted sub-
cutaneously in nude mice. In these studies we observed a marked
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Figure 2 In vivo tumour growth and phenotype of hSef over-expressing cells. (A) Graph of mean tumour volume changes over time for DU145 wild-type
(DU wt), DU145-EV and DU145-Sef clones. One representative of two repeat studies is shown with each point representing the mean volumes of all
tumours in the individual group (*P¼ 0.0001 and **P¼ 0.03 for mean tumour volume at the end of study comparing DU145-Sef with wild-type DU145 and
DU145-EV, respectively). Error bars represent s.d. from the mean. (B) H&E stain of representative tumour sections. The red arrows indicate areas of tumour
invasion into underlying muscle. (C) Immunoassaying for Ki67 as a marker of tumour proliferation. Numbers of positive nuclei were assessed as described in
the Materials and Methods and compared between tumours.
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difference in tumour growth and behaviour. Wild-type DU145
grew rapidly with a mean final tumour volume of 832ml by day 34
(Figure 2A). At this time point there was a significant difference in
the mean tumour volumes between wild-type DU145 tumours and
empty vector controls (326ml) and DU145-Sef tumours (55ml;
P¼ 0.003 and Po0.0001, respectively). DU145-EV tumours grew
more slowly but progressively enlarged, with all animals killed by
day 70 (mean final tumour volume 535ml). Tumours expressing
hSef, however, developed very slowly with mean final tumour
volumes (196ml) significantly lower than the comparative wild-
type (P¼ 0.0001) and empty vector control (P¼ 0.03). No animal
in this group required killing before the maximum time allowed
for the study (100 days). Microscopy of the harvested tumours
revealed extensive muscle invasion by tumours produced by
DU145 and DU145-EV cells in keeping with the expected
malignant phenotype (Figure 2B). In contrast, DU145-Sef tumours
showed a much less aggressive phenotype with minimal invasion
of the underlying muscle. Sections of tumour were then
immunoassayed for Ki67 as a measure of tumour proliferation.
In this study we found numerous proliferating cells in both wild-
type and DU145-EV cells (Figure 2C). However, DU145-Sef
tumours showed significantly fewer Ki67-positive cells consistent
with a slowly proliferating phenotype (P¼ 0.0004 compared with
wild-type and P¼ 0.0002 with DU145-EV). These findings suggest
that hSef has a significant inhibitory effect on in vivo prostate
tumour growth.
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Figure 3 hSef regulation of FGF-induced MAPK signalling. (A) Proliferation assays using FGF1, FGF2 and FGF8 in control and hSef-expressing clones (left
panel) and at different doses (right panels). The mean of three experiments, each repeated in triplicate, is shown and expressed as a fold change over un-
induced cells. (B) Phosphorylation of ERK in response to FGF stimulation over timed intervals with corresponding total ERK levels. One representative of
three experiments is shown. (C) Immunofluorescence for activated ERK with and without 10 ngml1 FGF2 stimulation. Nuclear expression of ERK is shown
by white arrows. One representative of three experiments is shown. (D) Co-transfection of an Elk1 reporter was used to test the effect of hSef on gene
transactivation. In these studies the mean of three experiments, each repeated in triplicate, is shown and expressed as a fold change in luciferase activity over
un-induced cells (*Po0.005 with error bars representing s.d. from the mean).
Sef inhibits FGF signalling in prostate cancer
S Darby et al
1895
British Journal of Cancer (2009) 101(11), 1891 – 1899& 2009 Cancer Research UK
M
o
le
c
u
la
r
D
ia
g
n
o
st
ic
s
hSef attenuates multiple FGF ligand-induced MAPK
activation
We next tested the effect of hSef expression on FGF-induced
signalling in prostate cancer cells. In these studies, hSef blocked
cell proliferation in response to different FGFs (Figure 3A, left
panel). This inhibitory effect was evident despite increasing levels
of the ligand (Figure 3A, right panel). We then tested the effect of
hSef on activation of the MAPK pathway. In DU145-EV cells the
addition of FGF1 and 8 resulted in rapid phosphorylation of ERK
(Figure 3B). However, this response was significantly reduced in
cells expressing hSef. In these cells, both the intensity and duration
of ERK phosphorylation was reduced. FGF stimulation also
resulted in rapid nuclear accumulation of pERK in DU145-EV
cells. In contrast, we could not detect pERK in the nuclei of
DU145-Sef cells, either with or without ligand stimulation
(Figure 3C). An Elk 1 reporter gene was next transfected into
our cell models to test whether the observed effect resulted in a
change in target gene transcription. In these studies, FGF 1, 2 and 8
enhanced Elk 1 activation in control DU145-EV cells in a dose-
dependent manner. However, hSef expression efficiently blocked
Elk 1 activation in response to FGFs irrespective of the ligand dose
used, confirming the inhibitory effects on ERK activation
(Figure 3D).
The inhibitory function of hSef is reversed by
ectopic expression of active Ras
To analyse the site of hSef action in prostate cancer cells, we co-
transfected a constitutively active Ras construct. Functional effects
were confirmed by the presence of ligand-independent sustained
ERK phosphorylation in control DU145-EV cells (Figure 4A). This
effect was also observed in DU145-Sef cells, suggesting that active
Ras was able to overcome its inhibitory effects on ERK phos-
phorylation. These findings were further confirmed in IF studies in
which the presence of active Ras restored pERK accumulation in
the nucleus of DU145-Sef cells (Figure 4B). We next tested whether
this translated into a change in cell behaviour. The presence of
active Ras reversed the inhibitory effects of hSef and increased cell
proliferation to similar levels observed in DU145-EV cells
(Figure 4C). A similar effect was observed in invasion assays in
which the presence of active Ras significantly enhanced cell
movement, whereas FGF stimulation alone failed to have any effect
on DU145-Sef cells (Figure 4D). These results suggest that the
point of hSef action in prostate cancer cells is likely to be either
above or at the level of Ras. Active Ras can overcome the
inhibitory effects of hSef in prostate cancer cells.
hSef protein is downregulated in high-grade
and metastatic clinical disease
We next analysed the pattern of hSef protein expression in clinical
tissue. The hSef antibody used for the study was first tested in a
panel of control tissue. In this analysis, the antibody detected hSef
in previously validated positive control kidney sections but not in
negative control placenta or in the presence of the blocking peptide
(Figures 5A–C, respectively) (Yang et al, 2003; Darby et al, 2006).
In benign biopsies (n¼ 43), 74% of cases (32 out of 43) expressed
strong levels of hSef and 9% had weak or absent signals (Figure 5D,
and Table 1). In contrast, only 21% (37 out of 176) of cancer
biopsies (n¼ 176) retained strong levels of hSef, whereas 25% had
weak or absent protein expression (Po0.0001) (Figures 5E and F
and Table 1). Areas of absent hSef expression in malignant cells
were also frequently found adjacent to strongly positive staining
benign glands (Figure 5G). Cancer biopsies were further analysed
by Gleason grade and stage; 44% (23 out of 52) of grade 3 cancers
retained strong expression of hSef, whereas this figure fell to only
6% (3 out of 53) among grade 5 cancers. Concomitantly, a greater
number of high-grade cancers had weak or absent hSef expression
(39% (19 out of 49) of grade 5 cancers compared with 6% (3 out of
52) of grade 3 cancers; Table 1A). Similar to our previous
transcript findings, there was no association with clinical stage in
this study (P¼ 0.053). In total, 141 cancers were informative for
metastatic status at presentation. hSef protein was weak or absent
in 46% (17 out of 37) of biopsies from men with bone metastasis.
In contrast, weak or absent signals were only observed in 17%
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Figure 4 Effect of Ras expression on hSef function. (A) Functional
effects of Ras expression was confirmed by assaying ERK activation using
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representative of three experiments is shown. One representative of three
experiments is shown (*Po0.005).
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(18 out of 104) of men without metastasis (Table 1A; Po0.0001).
hSef is known to have a long (full length) and short isoform, and
there are currently no isoform-specific hSef antibodies available.
The two isoforms are identical except that the shorter isoform
lacks a 144 aa sequence in the N-terminal region. To confirm
downregulation of the full-length Sef in our clinical series, mRNA
in situ hybridisation was performed using a probe to a unique
sequence of the full-length isoform. In a subset of prostate biopsies
(39 cancer and 10 benign samples), we observed strong expression
of hSef in benign prostates with anti-sense probes but not with
sense probes (Figures 5H and I, respectively). However, the signals
were significantly reduced in cancer samples (Figures 5J and K and
Table 1B). These results suggest that hSef is closely linked with
tumour aggressiveness, with reduced expression being a feature of
high-grade and metastatic clinical disease. Protein detection
showed loss of total hSef in high-grade cancer biopsies, and
in situ mRNA studies confirmed parallel loss of the full-length
transcript in prostate tumours.
DISCUSSION
Sef is closely expressed with FGFs in embryogenesis and exerts an
effect as a negative feedback regulator in preventing excessive
ligand-induced growth (Furthauer et al, 2002; Tsang et al, 2002).
This function is retained in adult tissue, suggesting a continued
role in determining the overall effect of cell stimulation by FGFs.
The reduced endogenous hSef expression in DU145 cells provides
an optimal model in which to analyse its function in prostate
cancer. In this cell model, we found that full-length hSef
significantly inhibited tumourigenic behaviour in vitro. These
findings are consistent with our converse observation in a different
cell line (PC3) that hSef silencing enhanced cancer cell prolifera-
tion and invasion (Darby et al, 2006). Thus, these complimentary
observations in two separate cell types provide strong evidence of a
tumour inhibitory function for hSef in prostate cancer. In vivo
studies provided further support for this notion as xenograft
tumours established from hSef-expressing cell showed very slow
tumour growth and a reduced ability to invade adjacent tissue
when compared with wild-type or vector only controls.
The site of hSef action is controversial with the key delineation
between function at the level of the receptor/Ras or at the level of
MEK. In this study the introduction of active Ras reversed the
inhibitory effects of hSef and resulted in increased ERK activation
and prostate cancer cell proliferation and invasive potential. These
results suggest that in prostate cancer cells hSef exerts an effect at
the level of the FGFR or at Ras. Functionality at this level is further
supported by the consistent finding of Sef interaction (colocalisa-
tion and immunoprecipitation) with the FGFR across different
species and cell types and its ability to inhibit both FGFR as well as
FRS phosphorylation (Tsang et al, 2002; Kovalenko et al, 2003,
2006; Xiong et al, 2003; Yang et al, 2003; Ren et al, 2007). The
ability of hSef to act upstream or at Ras would imply that it should
also inhibit alternate pathways activated by FGFR/Ras interaction,
which include PI3 kinase (Gioeli, 2005). In keeping with this, both
human and mouse Sef have been shown to block FGF induction
of the PI3 kinase pathway (Kovalenko et al, 2003; Ziv et al, 2006).
×100 ×100 ×100 ×100
×100×100×100
×200 ×200 ×200 ×200
Figure 5 Expression of hSef protein transcript in clinical tissue. (A) Strong hSef protein expression in positive control kidney tissue. (B) Lack of protein
expression in negative control placental tissue. (C) Addition of the blocking hSef peptide resulted in a loss of signals confirming antibody specificity.
(D) Strong positive protein expression in benign prostate glandular epithelium. (E) and (F) Significantly reduced levels of hSef protein expression in
malignant prostate glands. (G) Representative section showing positive hSef protein in benign glands (black arrow) and loss of expression in adjacent
malignant glands (red arrow). (H) In situ hybridisation with hSef full-length specific mRNA anti-sense probe showing strong expression in benign prostate
glands. (I) Lack of signals from hybridisation with a sense probe. (J, K). In situ hybridisation with hSef full-length mRNA anti-sense probe showing lack of
expression in malignant prostate glands.
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The exact mechanism of how hSef might inhibit FGFR/Ras
activation of MAPK signalling in prostate cancer cells is currently
unclear. Kovalenko et al (2006) have proposed that mSef may act
by interfering with FGFR dimerisation and hence prevent receptor
phosphorylation and downstream signalling. An alternative
mechanism is that hSef interacts directly with and inhibits Ras
activation by FGFR at the plasma membrane (Ren et al, 2006).
Functionality of hSef at this level would also provide an
explanation as to the lack of inhibitory function of the short
isoform in that the truncated sequence does not localise to the cell
membrane. Current work in our group is analysing the exact
mechanisms by which Sef might inhibit FGFR/Ras and MAPK
signalling in prostate cancer cells.
Only one human Sef (hSef) gene has been identified, although two
isoforms are known to exist (Rong et al, 2006; Ziv et al, 2006). Full-
length Sef is predicted to contain a signal peptide and transmem-
brane domain and is ubiquitously expressed in human tissues. The
short isoform is thought to be primarily cytosolic and has a more
restricted pattern of expression (Preger et al, 2004). Both human
isoforms have been shown to inhibit RTK signalling in cell line
models (Rong et al, 2006; Ziv et al, 2006). Differences in cell-specific
isoform function have been previously reported. In an elegant study
Ziv et al (2006) showed that full-length hSef inhibited MAPK
activation in epithelial cells but not in fibroblast cells. In contrast,
the short isoform of hSef inhibited MAPK activation in both cell
types. Work with the full-length mouse homologue, however,
showed that Sef was capable of blocking FGF-induced cell
proliferation in fibroblast cells and that this was associated with
decreased phosphorylation of Raf, MEK and ERK (Kovalenko et al,
2006). In this study we were only able to focus on the function of
full-length Sef and therefore cannot currently comment on the role
of the short isoform in prostate cancer cells. An analysis of
differences in function between these isoforms would be of great
interest and we are developing cell models to undertake this.
hSef transcript expression has been shown to be downregu-
ated in different epithelial malignancies. However, changes at the
transcript level may not necessarily translate into a loss of
expression at the protein level. In a large clinical cohort, we
observed reduced total hSef protein levels in a significant number
of cancers compared with benign biopsies. Further analysis of the
cancer group showed that downregulation was most evident in
high-grade and metastatic tumours. Reduced hSef levels, therefore,
do not seem to be an early event in prostate carcinogenesis but is
likely to be acquired in the transition to aggressive clinical disease.
These findings validate previous reports of reduced hSef transcript
expression in aggressive disease (Darby et al, 2006). The antibody
available to us could not differentiate between the two isoforms of
hSef. To corroborate our functional data, we wanted to specifically
test whether the full-length isoform of hSef was downregulated in
cancer. We therefore studied specific expression of full-length hSef
by in situ hybridisation using probes specific for the unique
segment of the long isoform. In these studies, we observed an
identical trend of reduced expression in malignant glands but
intact expression in benign glands.
In this study we have primarily analysed the role of hSef in FGF-
induced MAPK signalling. However, we would hypothesise that
hSef action at the level of the plasma membrane would allow it to
interact with different receptors and diverse downstream signals
that originate from this level. The profound anti-tumourigenic
effect of hSef on xenograft tumours in this study, despite the com-
plex in vivo environment, would support this notion. hSef has been
reported to interact with both nerve growth factor (NGF) and
epidermal growth factor (EGF) signalling (Xiong et al, 2003; Torii
et al, 2004; Ziv et al, 2006). Silencing of hSef has further been shown
to accelerate EGF-stimulated proliferation of cervical carcinoma
cells in vitro (Zisman-Rozen et al, 2007). More recently, Ren et al
(2008) reported evidence that hSef interacts and co-localises with
the EGF receptor. Intriguingly, in this paper, hSef attenuated EGFR
degradation and enhanced EGF-mediated MAPK signalling, adding
further diversity in cell-specific function to its role.
The in vitro, in vivo and clinical results in this study, as well as
that of our previous work, strongly support the notion of a tumour
suppressor function for hSef. On the basis of these data, we suggest
the following model for hSef function: in benign prostate cells, hSef
functions as an inducible feedback inhibitor as part of the normal
homeostatic mechanism. In these cells, hSef attenuates the effect
and duration of receptor signal transduction. It thus limits the
effect of mitogenic stimulation by FGFs. In prostate cancer,
however, expression of hSef is reduced by mechanisms that are as
yet unknown but are common to both isoforms. In these cells, the
loss of hSef results in growth factor signalling that is unopposed by
this normal regulatory mechanism and can result in un-attenuated
downstream signalling. Prostate cancer tumours also frequently
over-express FGF ligands and their cognate receptors and this can
further enhance mitogenic signalling. The loss of hSef, therefore, is
not in itself an oncogenic event but has an important permissive
role in enhancing growth factor stimulation in prostate cancer.
This hypothesis is supported by others who have similarly found
that the loss of hSef can augment receptor tyrosine kinase
signalling in cancer cells (Zisman-Rozen et al, 2007).
Multiple alterations are known to occur in the FGF axis in
prostate cancer. The contribution that loss of Sef might make in
the context of concomitant changes in FGF ligands and receptors is
therefore of great interest and is currently being analysed in our
unit (manuscript in preparation). The current tissue microarray
has previously been used to profile FGFR1 and FGFR4 expression
(Sahadevan et al, 2007). In a preliminary analysis of our series,
we tested whether loss of Sef may be related to FGFR1 or FGFR4
over-expression. Sef loss was observed in 57% of tumours with
weak or moderate levels of FGFR1 and also in 38% of tumours with
strong FGFR1 expression (P¼ 0.27). Similarly, loss of Sef was
observed in 44% of tumours with weak or moderate FGFR4 expres-
sion and also in 41% of tumours with strong FGFR4 expression
(P¼ 0.81). These data suggest that Sef downregulation does not
Table 1 Analysis of hSef expression in association with clinical disease
parameters
hSef protein
All tissue samples (n¼ 219) /+ ++ +++
(A)
Benign (n¼ 43) 4 7 32
Cancer (n¼ 176) 45 94 37 Po0.0001
Cancer tissues samples (n¼ 176)
Gleason grade 3 3 26 23
Gleason grade 4 23 41 11 Po0.0001
Gleason grade 5 19 27 3
Stage 1 11 32 16
Stage 2 6 18 5
Stage 3 15 17 5
Stage 4 7 13 2 P¼ 0.053
Bone metastasis 17 19 1
No metastasis 18 56 30 Po0.0001
(B)
hSef mRNA (full length)
Benign (n¼ 10) 2 3 5
Cancer (n¼ 10) 19 13 7 P¼ 0.04
Gleason grade 3 2 3 4
Gleason grade 4 4 5 3
Gleason grade 5 13 5 0 P¼ 0.006
Abbreviation: Stage¼ local tumour stage. A: Protein expression of total hSef analysed
by clinical parameters in 219 tissue samples. B: Specific hSef full-length isoform
expression by in situ hybridisation in a subset (n¼ 49) of benign and cancer tissue
samples.
Sef inhibits FGF signalling in prostate cancer
S Darby et al
1898
British Journal of Cancer (2009) 101(11), 1891 – 1899 & 2009 Cancer Research UK
M
o
le
c
u
la
r
D
ia
g
n
o
stic
s
seem to be associated with alterations in FGFR expression in
prostate cancer. We next tested whether concomitant loss of Sef
and increased FGFR expression may have relevance to tumour
behaviour. In tumours with strong FGFR1 expression but weak or
absent Sef levels, 71% had evidence of bone metastasis. In contrast,
in tumours with strong FGFR1 expression as well as strong Sef
expression, only 24% had evidence of bone metastasis (Po0.001).
A similar observation was made when tumours with strong FGFR4
expression was stratified by differences in Sef expression level.
These results support the notion that the loss of Sef may have a key
role in enhancing FGF signalling and promoting an aggressive
clinical phenotype.
The mechanism that downregulates hSef in cancer cells is
currently unknown. A potential mechanism may be by DNA
methylation, as has been shown with Sprouty 2 (McKie et al, 2005).
Another possibility is alterations at the genomic level. In this
context, Braga et al (2002) have previously reported frequent
LOH in chromosome 3p in the locality in which the hSef gene is
found. Targeting the mechanisms that downregulate hSef may
therefore be a useful method to restore expression levels and its
inhibitory effect on FGF stimulation. Assessing tumour expression
of hSef, however, may provide an idea of the likely effectiveness of
targeted receptor inhibition and help improve growth factor-based
therapy for clinical prostate cancer. Our ongoing work is focused
on addressing these issues as well as on analysing the role of the
short isoform and the exact mechanism by which hSef has its
function.
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